Sort
10,766 grants matching “checkpoint inhibitor”
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$404,582Yin Wang · University Of Maryland Baltimore · R01 · FY2022 · CA
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$404,553Mark W Jackson · Case Western Reserve University · R01 · FY2022 · CA
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$404,553Mark W Jackson · Case Western Reserve University · R01 · FY2023 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$404,550Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$404,489Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
$404,457Ralph R Weichselbaum · University Of Chicago · R01 · FY2022 · CA
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
$404,457Ralph R Weichselbaum · University Of Chicago · R01 · FY2023 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$404,265Pan Zheng · University Of Maryland Baltimore · R01 · FY2019 · CA
Covalent Protein Binders for Cancer Research and Therapy
$404,218Lei Wang · University Of California, San Francisco · R01 · FY2025 · CA
Effects of androgen receptor antagonists on human T cell function
$404,168Susan E Murray · University Of Portland · R15 · FY2022 · CA
Development of IDO PET agents for immunotherapy
$404,087Zibo Li · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
Development of IDO PET agents for immunotherapy
$404,087Zibo Li · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Development of IDO PET agents for immunotherapy
$404,087Zibo Li · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA
Retroviral RLI immunomodulatory gene therapy for glioblastoma
$403,750Manish Aghi · University Of California, San Francisco · R01 · FY2022 · NS
Retroviral RLI immunomodulatory gene therapy for glioblastoma
$403,750Manish Aghi · University Of California, San Francisco · R01 · FY2023 · NS
Retroviral RLI immunomodulatory gene therapy for glioblastoma
$403,750Manish Aghi · University Of California, San Francisco · R01 · FY2025 · NS
Endocytic Control of Autophagosome Formation in Lupus T cells
$403,750Andras Perl · Upstate Medical University · R01 · FY2016 · AI
T cell fate decisions and transplant outcomes
$403,750Xian Chang Li · Methodist Hospital Research Institute · R01 · FY2022 · AI
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$403,742Mei Kong · University Of California-Irvine · R01 · FY2024 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies
$403,612Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2020 · CA
Targeting vulnerabilities of PPM1D-mutant gliomas
$403,607Pratiti Bandopadhayay · Dana-Farber Cancer Inst · R37 · FY2022 · CA
Targeting vulnerabilities of PPM1D-mutant gliomas
$403,607Pratiti Bandopadhayay · Dana-Farber Cancer Inst · R37 · FY2025 · CA
Deciphering MDSC function for GBM targeting
$403,517Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · NS
Small Molecule Activators of Procaspases as Anti-Cancer Agents
$403,284Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2020 · CA
Small Molecule Activators of Procaspases as Anti-Cancer Agents
$403,281Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2021 · CA